TDLNs are the primary sites for the development of adaptive antitumor immunity, where activated DCs present tumor-related antigens to CD4+ and CD8+ T cells, leading to cytotoxic T cell activation and tumor clearance (24). This evidence concerns the gene CD8A and neoplasm.